263 related articles for article (PubMed ID: 33110239)
1. Novel uses of immunohistochemistry in breast pathology: interpretation and pitfalls.
Cimino-Mathews A
Mod Pathol; 2021 Jan; 34(Suppl 1):62-77. PubMed ID: 33110239
[TBL] [Abstract][Full Text] [Related]
2. Utility of Sox10 labeling in metastatic breast carcinomas.
Nelson ER; Sharma R; Argani P; Cimino-Mathews A
Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
[TBL] [Abstract][Full Text] [Related]
3. TRPS1, GATA3, and SOX10 expression in triple-negative breast carcinoma.
Yoon EC; Wang G; Parkinson B; Huo L; Peng Y; Wang J; Salisbury T; Wu Y; Chen H; Albarracin CT; Resetkova E; Middleton LP; Krishnamurthy S; Gan Q; Sun H; Huang X; Shen T; Chen W; Parwani AV; Sahin AA; Li Z; Ding Q
Hum Pathol; 2022 Jul; 125():97-107. PubMed ID: 35413381
[TBL] [Abstract][Full Text] [Related]
4. SOX10 and GATA3 in Adenoid Cystic Carcinoma and Polymorphous Adenocarcinoma.
Adkins BD; Geromes A; Zhang LY; Chernock R; Kimmelshue K; Lewis J; Ely K
Head Neck Pathol; 2020 Jun; 14(2):406-411. PubMed ID: 31222589
[TBL] [Abstract][Full Text] [Related]
5. A combination of GATA3 and SOX10 is useful for the diagnosis of metastatic triple-negative breast cancer.
Tozbikian GH; Zynger DL
Hum Pathol; 2019 Mar; 85():221-227. PubMed ID: 30468800
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic utility and sensitivities of matrix Gla protein (MGP), TRPS1 and GATA3 in breast cancer: focusing on metastatic breast cancer, invasive breast carcinoma with special features, and salivary gland-type tumours.
Wu Y; Chen F; Pan L; Chao X; Li M; Luo R; Chen K; Zheng C; Du T; He J; Sun P
Pathology; 2024 Jun; 56(4):516-527. PubMed ID: 38570266
[TBL] [Abstract][Full Text] [Related]
7. Sry-related high-mobility-group/HMG box 10 (SOX10) as a sensitive marker for triple-negative breast cancer.
Jamidi SK; Hu J; Aphivatanasiri C; Tsang JY; Poon IK; Li JJ; Chan SK; Cheung SY; Tse GM
Histopathology; 2020 Dec; 77(6):936-948. PubMed ID: 32304249
[TBL] [Abstract][Full Text] [Related]
8. SOX10 expression in mammary invasive ductal carcinomas and benign breast tissue.
Chiu K; Ionescu DN; Hayes M
Virchows Arch; 2019 Jun; 474(6):667-672. PubMed ID: 30903273
[TBL] [Abstract][Full Text] [Related]
9. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas.
Cimino-Mathews A; Subhawong AP; Elwood H; Warzecha HN; Sharma R; Park BH; Taube JM; Illei PB; Argani P
Hum Pathol; 2013 Jun; 44(6):959-65. PubMed ID: 23260325
[TBL] [Abstract][Full Text] [Related]
10. S-100 protein and SOX10-positive breast carcinoma mimicking metastatic melanoma.
Newman J; Brahmbhatt M; Stoff BK; Martinez AP
J Cutan Pathol; 2020 Dec; 47(12):1187-1191. PubMed ID: 32710508
[TBL] [Abstract][Full Text] [Related]
11. MYB RNA In Situ Hybridization Is a Useful Diagnostic Tool to Distinguish Breast Adenoid Cystic Carcinoma From Other Triple-negative Breast Carcinomas.
Butcher MR; White MJ; Rooper LM; Argani P; Cimino-Mathews A
Am J Surg Pathol; 2022 Jul; 46(7):878-888. PubMed ID: 35522890
[TBL] [Abstract][Full Text] [Related]
12. Combined use of SOX10 and GATA3 in mammary carcinoma.
Qazi MS; McGregor SM
Pathol Res Pract; 2020 Feb; 216(2):152801. PubMed ID: 31924335
[TBL] [Abstract][Full Text] [Related]
13. The Added Value of SOX10 Immunohistochemistry to Other Breast Markers in Identifying Cytokeratin 5-Positive Triple Negative Breast Cancers as of Mammary Origin.
Sejben A; Vörös A; Golan A; Zombori T; Cserni G
Pathobiology; 2021; 88(3):228-233. PubMed ID: 33567441
[TBL] [Abstract][Full Text] [Related]
14. Problematic breast tumors reassessed in light of novel molecular data.
Pareja F; Weigelt B; Reis-Filho JS
Mod Pathol; 2021 Jan; 34(Suppl 1):38-47. PubMed ID: 33024304
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological, immunohistochemical and molecular correlation of neural crest transcription factor SOX10 expression in triple-negative breast carcinoma.
Harbhajanka A; Chahar S; Miskimen K; Silverman P; Harris L; Williams N; Varadan V; Gilmore H
Hum Pathol; 2018 Oct; 80():163-169. PubMed ID: 29894722
[TBL] [Abstract][Full Text] [Related]
16. SOX10, GATA3, GCDFP15, Androgen Receptor, and Mammaglobin for the Differential Diagnosis Between Triple-negative Breast Cancer and TTF1-negative Lung Adenocarcinoma.
Laurent E; Begueret H; Bonhomme B; Veillon R; Thumerel M; Velasco V; Brouste V; Hoppe S; Fournier M; Grellety T; MacGrogan G
Am J Surg Pathol; 2019 Mar; 43(3):293-302. PubMed ID: 30628926
[TBL] [Abstract][Full Text] [Related]
17. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast carcinomas of low malignant potential: review on diagnostic criteria and differential diagnoses.
Cima L; Kaya H; Marchiò C; Nishimura R; Wen HY; Fabbri VP; Foschini MP
Virchows Arch; 2022 Jan; 480(1):109-126. PubMed ID: 34458945
[TBL] [Abstract][Full Text] [Related]
19. The Utility of SOX10 Immunohistochemical Staining in Breast Pathology.
Rammal R; Goel K; Elishaev E; Rinda Soong T; Jones MW; Zhao C; Clark BZ; Carter GJ; Yu J; Fine JL; Villatoro TM; Harinath L; Bhargava R
Am J Clin Pathol; 2022 Nov; 158(5):616-625. PubMed ID: 36000970
[TBL] [Abstract][Full Text] [Related]
20. The role of GATA3 in breast carcinomas: a review.
Asch-Kendrick R; Cimino-Mathews A
Hum Pathol; 2016 Feb; 48():37-47. PubMed ID: 26772397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
